Upgrade to SI Premium - Free Trial

Truist on Gilead Sciences (GILD): 'old Rush: $2B Deal for Ouro Adds I&I Strength with BCMAxCD3 TCE in Orphan Autoimmune Indications

March 24, 2026 5:23 AM
Truist Securities analyst Greg Renza reiterated a Buy rating and $152.00 price target on Gilead Sciences (NASDAQ: GILD).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments